KISS10
Fragment of kisspeptin that stimulates GnRH release, playing a key role in puberty initiation and reproductive function.
Regulatory status (as of Sept 2026)
Not FDA-approved; investigational.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote4 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Kisspeptin-10 is a compound with only early, small human studies so far. Fragment of kisspeptin that stimulates GnRH release, playing a key role in puberty initiation and reproductive function.
| Half-life | Kisspeptin-10: about 4 min (mice, IV/systemic) detailsKisspeptin-10: ~4 min (mice, IV/systemic); ~28 min (27.6 ± 1.1) is kisspeptin-54 in human males (IV infusion) |
|---|---|
| How it's given in studies | Subcutaneous or IV injection |
| Research stage | Phase 1 / early human |
| Dosing | Published research: Healthy men: IV bolus 0.01-3.0 µg/kg detailsHealthy men: IV bolus 0.01-3.0 µg/kg (max LH response at 1 µg/kg; 3 µg/kg blunted); IV infusion 1.5-4 µg/kg/h.Community-reportedCommunity-reported: 1–10 mcg/kg, subcutaneous or IV injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It signals the brain to release the hormones that control the reproductive system. Activates GnRH neurons to stimulate pituitary release of LH and FSH.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 1 to 10 mcg/kg (subcutaneous or IV injection). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Kisspeptin-10 | Kisspeptin-10: ~4 min (mice, IV/systemic); ~28 min (27.6 ± 1.1) is kisspeptin-54 in human males (IV infusion) | Subcutaneous or IV injection | Phase 1 / early human |
| Gonadorelin | No published PK data found | Subcutaneous injection | Discontinued |
| PT-141 (Bremelanotide) | No published PK data found | Subcutaneous injection | FDA-approved |
| Triptorelin | Geometric mean terminal half-life 2.8 h in healthy males after a 0.5 mg IV bolus; 6.6-7.7 h in males with renal or hepatic impairment (three-compartment model) | Intramuscular injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Sexual Health category. View All Sexual Health Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.